GickyRervais
Posted - 18 hours ago
$RYTM Signal sent. 4 shares traded at 6:30am. We are going higher.
Thestocktraderhubzee
Posted - 1 day ago
WATCHLIST DEC 23 2024
$RYTM hythm Pharmaceuticals Secures FDA Approval For Expanded Use Of IMCIVREE To Treat Obesity In Children As Young As 2 With Bardet-Biedl Syndrome Or MC4R Pathway Deficiencies, Targeting Rare Neuroendocrine Diseases
$QBTS Benchmark Maintains Buy on D-Wave Quantum, Raises Price Target to $8
$BLDP Ballard Power Systems shares are trading higher after the company announced multiple orders totaling over 6 MW of fuel cell engines for the European bus market.
$PFE FDA Grants Accelerated Approval To Encorafenib With Cetuximab And mFOLFOX6 For Metastatic Colorectal Cancer With A BRAF V600E Mutation
$JOBY Joby Aviation shares are trading higher after the company announced it has conducted its first FAA testing under the Type Inspection Authorization, marking the start of the final phase of its certification program.
ZRadly
Posted - 2 days ago
$RYTM 😉
ZRadly
Posted - 3 days ago
$RYTM 😉
1986iamwallstreet
Posted - 4 days ago
$RYTM market cap only 3.5 billion will get bought out 🔜 …….
1986iamwallstreet
Posted - 4 days ago
Rhythm Pharmaceuticals Secures FDA Approval For Expanded Use Of IMCIVREE To Treat Obesity In Children As Young As 2 With Bardet-Biedl Syndrome Or MC4R Pathway Deficiencies, Targeting Rare Neuroendocrine Diseases $RYTM
1986iamwallstreet
Posted - 4 days ago
$RYTM Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
Quantumup
Posted - 4 days ago
Oppenheimer🏁 $RYTM OP; $76~OPY sees meaningful⬆️side in '25/beyond as $RYTM pursues a multi-$B TAM: The pharmaceutical weight management revolution continues to galvanize investor attention, with Rhythm Pharma distinguished by its focus on rare obesity disorders for which commonly-prescribed drugs are poorly suited. As the company steadily builds a business through Imcivree's global commercialization for several genetically-driven diseases, our revenue outlook in hypothalamic obesity-an acquired condition for which we see high likelihood of development success-drives our enthusiasm ahead of 1H25 Phase 3 results. Leadership in MC4 biology should position RYTM for enduring prosperity as Imcivree's indications further expand, pipeline candidates offering clinical and convenience advantages progress in development, and a broad-based effort toward patient finding among genetic obesities bears fruit. We see meaningful upside in 2025 and beyond as RYTM pursues a multi-billion-Pdollar TAM.
TeeMan123
Posted - 5 days ago
$RYTM great to see this name finally joining the top m&a prospects list. I’ve been here since it was in the $3s… and generally think the appropriate take out price is $110
GickyRervais
Posted - 5 days ago
$RYTM I hope you used this recent pullback as an opportunity to establish or add to your position.
Quantumup
Posted - 5 days ago
Stifel Named $RYTM, $SLNO, and $VERV as its 2025 BioTech Top Picks: $LLY $XBI
GickyRervais
Posted - 5 days ago
$RYTM BBS commercial launch underway I Wales and UK. Q4 sales ramping up.
TeeMan123
Posted - 5 days ago
$RYTM Wells Fargo Securities makes RYTM their signature pick for 2025!!
rahmanoof
Posted - 1 week ago
@HenryDotDotDot Fair point . If approval kicks in, institutional interest and algo support can create momentum, before that it will not just like I saw with $RYTM. Let’s see how it unfolds
rahmanoof
Posted - 1 week ago
I was there in $rytm when it hits 52 weeks low after approval , then it flied to 20+ in 6 months
Tumble51
Posted - 2 weeks ago
$RYTM Ahhh did I hit a nerve , Tuff S !
TobiramaSendzhu
Posted - 2 weeks ago
$RYTM
Tumble51
Posted - 2 weeks ago
$RYTM along with RYTM 3.0 , Goldman wants out after 2 years …put s BUY on it !! Knowing the short of the float is at 15% !!!
Tumble51
Posted - 2 weeks ago
$RYTM Goldman is tired …held this for 2 years from $3 , thought David Meeker would sell by now , it is bye bye time , thus the BUY , for fools to Buy their stock from their inventory.
Quantumup
Posted - 2 weeks ago
Goldman Sachs⬆️the price target on Rhythm Pharmaceuticals ( $RYTM ) to $66 was $59 and reiterated at a Buy rating. RYTM is +805.1% (vs. +20.7% in the XBI) since July 12, 2022, the date the company presented first data from its Ph2 open label study of setmelanotide in hypothalamic obesity (HO). With the highly anticipated Ph3 readout of the agent in this setting rapidly approaching (expected 1H25), we revisit prior data and the trial's structure to understand the setup for the stock ahead of these results:
abcdzepeda
Posted - 2 weeks ago
$RYTM Hmmmmm? After hours$$$$
abcdzepeda
Posted - 3 weeks ago
$RYTM Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
NVDAMillionaire
Posted - 4 weeks ago
$RYTM Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Consistent Execution Driving Growth in Rare Disease Franchise https://beyondspx.com/article/rhythm-pharmaceuticals-inc-nasdaq-rytm-consistent-execution-driving-growth-in-rare-disease-franchise
TeeMan123
Posted - 1 month ago
$INZY $RYTM hey folks ,RYTM 2.0 is here!!
TickerDD_com
Posted - 1 month ago
Play Stonk Trivia! 5 Strangest Market Events for $RYTM and its company Rhythm Pharmaceuticals
https://youtu.be/wlLJdUJe9lk
abcdzepeda
Posted - 1 month ago
$RYTM The last time I checked this was a board for RYTM, can we please stop with the post for other tickers on this board (MYNZ) please. is there not a board for this ticker?
swingingtech
Posted - 1 month ago
$ALLY $RYTM $CACI
https://wallstreetwaves.com/key-thursday-options-insights-ally-rytm-caci/
net0trader
Posted - 1 month ago
@RonIsWrong have you looked at $RYTM lately? What a move so far and chart looks like it is not done yet
TeeMan123
Posted - 1 month ago
$RYTM in Meeker we trust... he will get top $ for this company, Roche should be all over it... can we get some merger chatter???
